Literature DB >> 18946592

Systemic Wegener's granulomatosis with severe orbito-ocular involvement.

J Chua1, L Lim.   

Abstract

Orbito-ocular involvement in Wegener's granulomatosis is the result of both focal ischaemic vasculitis and granulomatous soft tissue inflammation. Necrotising keratoscleritis and orbital inflammation are two most characteristic ophthalmic presentations. We describe a 56-year-old man with systemic limited Wegener's granulomatosis, presenting with pulmonary fibrosis, pansinusitis and left mastoiditis. This was complicated by the development of a left severe necrotising anterior scleritis, peripheral ulcerative keratitis and orbital apex syndrome. Both c-ANCA and anti-PR3 were positive. Despite mainstay systemic immunosuppressive therapy with cyclophosphamide and prednisolone, the visual prognosis remained very poor. This was largely due to the presence of an irreversible ischaemic optic neuropathy, extensive corneoscleral melt and corneal neovascularisation. This case highlights the possible extent of orbital and ocular surface involvement in Wegener's granulomatosis, and hence the importance of vigilance by the physician.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946592

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  3 in total

1.  The CT appearance of a corneal melt: report of 2 cases.

Authors:  A Bluestone; J Ackert; P M Som
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-22       Impact factor: 3.825

2.  Orbital apex syndrome secondary to granulomatosis with polyangiitis.

Authors:  Sarah Siddiqui; Andrew Jon Kinshuck; Venkat Ramanan Srinivasan
Journal:  BMJ Case Rep       Date:  2013-12-05

3.  A case report of the orbit, ocular association and the lung in granulomatosis with polyangiitis: A diagnostic challenge.

Authors:  Cheng-Wei Lu; Xiu-Fen Liu; Ying Luan; Cheng-Bo Lu; Dan-Dan Zhou; Li-Min Guo; Ya-Bin Sun; Sheng-Nan Chen; Yun-Long Wu; Ji-Long Hao
Journal:  Exp Ther Med       Date:  2017-04-28       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.